Climb Bio Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Aoife Brennan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureless than a year
Board average tenure4.5yrs

Recent management updates

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Mar 08
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Nov 18
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Aug 15

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Aug 02

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Jul 11

CEO

Aoife Brennan (48 yo)

no data

Tenure

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President and Director at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) Dr. Brennan serves as Director of Xilio Therapeutics...


Leadership Team

NamePositionTenureCompensationOwnership
Aoife Brennan
CEO, President & Directorno datano datano data
Brett Kaplan
COO & Principal Financial Officerless than a yearno datano data
Emily Pimblett
Chief Accounting Officer1.7yrsno data0.011%
$ 39.0k
Jo Palmer-Phillips
Chief Development Officerno datano datano data
Nishi Rampal
Senior Vice President of Clinical Developmentless than a yearno datano data

0.2yrs

Average Tenure

48yo

Average Age

Experienced Management: CLYM's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Aoife Brennan
CEO, President & Directorno datano datano data
Adam Rosenberg
Independent Director4yrsUS$77.16k0.27%
$ 919.0k
Liam Ratcliffe
Lead Independent Director5yrsUS$71.33k0%
$ 0
Simon Tate
Independent Director5.7yrsUS$22.52k0%
$ 0
Andrew Levin
Co-Founder & Chairman5.7yrsUS$87.91k0%
$ 0
Stephen Thomas
Directorless than a yearno data0.15%
$ 536.2k
Judith Dunn
Independent Director3.7yrsUS$69.66k0%
$ 0

4.5yrs

Average Tenure

54yo

Average Age

Experienced Board: CLYM's board of directors are considered experienced (4.5 years average tenure).